Phillips-Medisize, a US-based contract manufacturer to the medical device, drug delivery and pharmaceutical markets, has started production at the 6,000m2 expansion to its site in Kontiolahti, Finland.
The site focuses on the production of inhalers, insulin pens, transfer devices and syringes.
The expansion includes 1,200m2 of Class 8 cleanroom manufacturing and assembly, and has space for further expansion for moulding machines and assembly.
New high-speed automation lines enable the ramp up of multi-component, complex drug delivery devices from prototype to automated 24/7 mass production. The plant has multiple high-speed, fully automated assembly lines; fully automated printing lines; and several semi-automated lines.
Matt Jennings, President and CEO of Phillips-Medisize, said: 'The ISO 13485 multi-site QMS certified expansion brings our medical manufacturing square footage to over 92,900m2, with 25,000m2 of cleanroom. This, coupled with extensive in-house tooling, state-of-the-art metrology, high volume automated assembly capabilities, innovative technologies, and creative people, upholds our mission to provide the highest level of satisfaction to our customers.'
Phillips-Medisize has annual sales of US$500m with 75% coming from drug delivery, medical device, primary pharmaceutical packaging, and diagnostic products such as disposable insulin pens, glucose meters, inhalation drug delivery devices, single-use surgical devices and consumable diagnostic components.
